The City of London has long viewed the pharmaceutical industry as a reliable dividend machine, but the latest developments across the Atlantic are turning the sector into a political minefield. Canada’s booming market for generic semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes drug Ozempic, has laid bare the grotesque pricing disparities between the US and the rest of the world. For British taxpayers funding the NHS, the numbers are nothing short of scandalous.
Generic Ozempic, now widely available in Canadian pharmacies at a fraction of the US list price, is exposing the artificial scarcity and pricing power that Big Pharma enjoys south of the border. While American patients pay upwards of $1,000 per month for the branded version, Canadian generics can be had for as little as $150. The gap is a direct result of the US’s fragmented, profit-driven healthcare system, where insurers and pharmacy benefit managers negotiate opaque rebates, leaving patients and employers holding the bag.
For the NHS, which is perennially battling budget overruns, the potential savings are mouth-watering. The UK’s health service already procures drugs at lower prices than the US, but the Canadian generic boom suggests there is further room to squeeze margins. If NHS England can replicate Canada's market dynamics, it could save hundreds of millions annually on diabetes care alone. This is the kind of fiscal windfall that would make any chancellor smile.
But the implications go beyond simple procurement. The Canadian experience demonstrates that competition works when regulatory barriers are lowered. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has been slow to approve generic versions of complex biologics, partly due to lobbying from originator manufacturers. The Ontario generics boom shows that with political will, approval processes can be accelerated without compromising safety.
The US drug pricing scandal is not new to City analysts. We have long warned that the American model is unsustainable, propped up by a cocktail of patent evergreening, direct-to-consumer advertising, and a captive insurance system. What is new is the embarrassment of having a polite northern neighbour demonstrate a better way. The US pharma lobby’s arguments about research costs ring hollow when Canadian generics are produced at a fraction of the price by firms that still turn a profit.
There is, of course, a risk of capital flight. If US drugmakers face margin compression at home, they may shift R&D investment elsewhere. But as any portfolio manager knows, innovation thrives on competition, not rent-seeking. The UK should seize this moment to negotiate harder with suppliers. The NHS already has a powerful tool in the form of the brand-to-generic substitution policy, but it has been timid in wielding it for high-cost biologics.
Gilt yields have been volatile recently, but a serious commitment to NHS cost control would be bond-positive. The market would reward a government that tackles the structural deficit in healthcare spending. With the NHS facing a £160 billion backlog, every saving matters. The Canadian generic Ozempic explosion is a wake-up call: the City should buy healthcare cost-containment stories, not just pharma names.
Central bankers, too, should take note. Sticky inflation in the service sector has been partly driven by healthcare costs. A more competitive drug market would ease pressure on the consumer price index. The Bank of England could use this as a reason to hold off on further rate hikes, a prospect that would delight the gilt market.
The moral of this story is simple: markets work when they are allowed to. The US drug pricing model is a perversion of capitalism, a system where middlemen extract rents and patients pay the price. Canada has shown the way. The NHS must follow. If not, British taxpayers will continue to subsidise the world’s most expensive healthcare system. And that, dear readers, is a scandal that will not sit well with any prudent investor.
